Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mDCt survivin
- Development stage
- Phase 3
- Lead developer
- Oslo University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
mDCt survivin is an autologous dendritic cell-based cancer vaccine developed by Oslo University Hospital. It consists of patient-derived mature dendritic cells (mDCs) transfected via electroporation with in vitro-transcribed (ivt) mRNA encoding survivin (BIRC5), an anti-apoptotic protein highly expressed in glioblastoma and cancer stem cells. Upon administration, these dendritic cells present survivin-derived peptides on their surface to stimulate a robust, antigen-specific cytotoxic T-lymphocyte (CTL) response against survivin-expressing tumor cells. In clinical trials, such as the DEN-STEM trial for newly diagnosed glioblastoma, mDCt survivin is evaluated as part of a trivalent immunotherapy regimen alongside mDCt hTERT and mDCt auto, combined with standard chemoradiotherapy (temozolomide).
- Other names
- mature dendritic cells transfected with survivin mRNAmDCt-survivinsurvivin mRNA-transfected dendritic cellssurvivin mRNA-transfected mature dendritic cells
02
Targets
γδ TCR (T-cell receptor)BIRC5 (Survivin)Survivin-HLA (Survivin-derived peptide-HLA complexes)
Beyond the preview
Go deeper on mDCt survivin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mDCt survivin.